Results 161 to 170 of about 130,425 (315)

OGFRL1 deficiency causes CRMO via pathological osteoclastogenesis, with therapeutic response to TNF inhibitor

Arthritis &Rheumatology, Accepted Article.
Objectives To verify the pathogenesis of the OGFRL1 loss‐of‐function variant (c.30del, p. F10Ffs*110) identified in a CRMO patient and investigate the underlying mechanism. Methods Whole exome sequencing and Sanger sequencing were performed to identify and confirm the variant.
Wen Xiong, Yusha Wang, Tingyan He, Jinjian Fu, Ying Luo, Jinbo Wang, Jun Wang, Xiaomin Yu, Qing Zhou, Jun Yang   +9 more
wiley   +1 more source

Advances on drug therapy for KRAS^G12C-mutant non-small-cell lung cancer. [PDF]

Transl Oncol
Tian T, Li W.
europepmc   +1 more source

Krš ili kras? Krš!

Geografski horizont, 2008
U radu se iznosi opravdanost termina krš i razlozi zbog kojih taj termin ima prednost pred terminom kras.
openaire   +3 more sources

Impact of extended insurance coverage on survival outcomes among patients with metastatic colorectal cancer in Taiwan

British Journal of Clinical Pharmacology, EarlyView.
Aims Predetermined treatment duration limits (PTDLs) are often used by Taiwan's National Health Insurance Administration to contain healthcare costs, but they may compromise patient outcomes. Therefore, we studied Taiwan's 2017 extension of the bevacizumab PTDL from 24 to 36 weeks in metastatic colorectal cancer (mCRC) to evaluate whether prolonged ...
Wei‐Ming Huang, Chen‐Han Chueh, Chien‐Yu Tseng, Christopher N. Kaufmann, Earl J. Morris, Chiao‐En Wu, Yi‐Wen Tsai   +6 more
wiley   +1 more source

RAS Mutation-Specific Responses to Paralog- and State-Selective RAS Inhibitors. [PDF]

Mol Cancer Res
Baars B, Orive-Ramos A, Emmett MJ, Gaire B, Desaunay M, Kou Z, Li G, Adamopoulos C, Aaronson SA, Wang S, Sellers WR, Martin T, Gavathiotis E, Poulikakos PI.   +13 more
europepmc   +1 more source

Silencing KRAS [PDF]

Science-Business eXchange, 2014
openaire   +1 more source

Clinicopathological, molecular, and prognostic features of colorectal carcinomas with KRAS c.34G>T (p.G12C) mutation [PDF]

Satoko Ugai, Qian Yao, Yasutoshi Takashima, Yuxue Zhong, Kosuke Matsuda, Hidetaka Kawamura, Yu Imamura, Kazuo Okadome, Kosuke Mima, Kota Arima, Keisuke Kosumi, Mingyang Song, Jeffrey A. Meyerhardt, Marios Giannakis, Jonathan A. Nowak, Tomotaka Ugai, Shuji Ogino   +16 more
openalex   +1 more source

Protocols to evaluate mutant specificity of an oncogene-targeting siRNA using orthogonal in vitro and in vivo approaches. [PDF]

STAR Protoc
Stanland LJ, Porrello A, Egli M, Pecot CV.   +3 more
europepmc   +1 more source

KRAS Positive [PDF]

, 2020
openaire   +1 more source

Supplementary Methods S1 from IND-Enabling Studies for a TCR-T Targeting a Pancreatic Cancer KRAS^G12V Mutation

Sizhen Wang, Guangrong Yu, Yanzhenzi Dai, Chi Gan, Shuyi Qiu, Xiaohui Zhang, Xiaochun Jiang, Ran Wei, Jiongming Yang, Dou Wu, Ling Chen, Lei Huang, Min Li, Yi Xiao, Rongxi Shen, Yimin Chen, Diling Zhu, Anlong Yao, Yonghao Ouyang, Zhufeng Sun, Xinbo Wang, Hong‐Ming Hu   +21 more
openalex   +1 more source